Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells

Stefan Lob (First author), Alfred Konigsrainer, Richard Schafer, Hans-Georg Rammensee, Gerhard Opelz, Peter Terness

    Research output: Contribution to journalOriginal Article (Journal)peer-review

    Abstract

    Clinical trials have been started with the aim of inducing tumor immunity by blocking the immunosuppressive action of indoleamine-2,3-dioxygenase (IDO) with the IDO2-inhibitor dextro-1-methyl-tryptophan (D-1MT). Here we show that human dendritic cells (DCs) express both IDO-1 and IDO-2, but that only IDO1 mediates tryptophan catabolism; furthermore, its activity is blocked by levo-1MT, whereas D-1MT is inefficient. Consequently, in humans any possible antitumor effects of D-1MT cannot be attributed to abrogation of IDO activity in DCs as described in this study.

    Original languageEnglish
    Pages (from-to)2152-4
    Number of pages3
    JournalBLOOD
    Volume111
    Issue number4
    DOIs
    Publication statusPublished - 15 Feb 2008

    Keywords

    • Cytokines/pharmacology
    • Dendritic Cells/drug effects
    • Gene Expression Regulation, Enzymologic
    • Humans
    • Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics
    • Kinetics
    • RNA, Small Interfering/genetics
    • Stereoisomerism
    • Transfection
    • Tryptophan/analogs & derivatives

    Fingerprint

    Dive into the research topics of 'Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells'. Together they form a unique fingerprint.

    Cite this